Inhibikase Therapeutics (IKT) FCF Margin (QoQ) (2020 - 2023)

Inhibikase Therapeutics (IKT) FCF Margin (QoQ) (2020 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Inhibikase Therapeutics 407.51 Mn 237.14 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 -34.42 Bn
Sep 30, 2023 -123,734.00
Jun 30, 2023 533,428.00
Mar 31, 2023 -366,133.00
Dec 31, 2022 7.27 Mn
Sep 30, 2022 -1.18 Mn
Jun 30, 2022 -5.79 Mn
Mar 31, 2022 20.21 Mn
Dec 31, 2021 -21.01 Mn
Sep 30, 2021 -30,360.00
Jun 30, 2021 -3,196.00
Mar 31, 2021 27,584.00
Dec 31, 2020 -75,583.00
Sep 30, 2020 20,174.00
Jun 30, 2020 9,300.00